<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119378">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957670</url>
  </required_header>
  <id_info>
    <org_study_id>LM001</org_study_id>
    <nct_id>NCT01957670</nct_id>
  </id_info>
  <brief_title>Pilot Study to Clinical Evaluate Device Prototypes in Dry Eye Patients</brief_title>
  <official_title>Pilot, Open-label, Single-Arm Study Designed to Clinically Evaluate Various Lacrima Medical Device Prototypes in Adult Patients With Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lacrima Medical LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lacrima Medical LTD</source>
  <oversight_info>
    <authority>Israel: The Israel National Institute for Health Policy Research and Health Services Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the safety, tolerability and feasibility of Lacrima investigational
      medical device to treat dry eye patients
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Lower Tear Meniscus Height using Optical Coherence Tomography</measure>
    <time_frame>up to 8 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale score</measure>
    <time_frame>up to 8 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment with Lacrima medical device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lacrima medical Prototypes</intervention_name>
    <arm_group_label>Treatment with Lacrima medical device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Male or female, 18 years of age and over at screening

          2. Diagnosis of mild to moderate Dry Eye, as defined by:

               1. Positive corneal fluorescein staining , defined as a corneal punctate
                  fluorescein staining score of ≥3 in either eye by the National Eye Institute
                  evaluation scale summed over 5 areas, each with a 0-3 scoring scale; AND

               2. Schirmer Test score (with anesthesia, 5 minutes &lt; 5 mm either eye) ; AND

               3. OSDI score of ≥12 and OSDI score of &lt;33

        Main Exclusion Criteria:

          1. Persistent intraocular inflammation or infection including conjunctivitis at the time
             of the study or 2 weeks prior to study start.

          2. Any concomitant active or history of eye disease including, but not limited to lid
             abnormalities, nasolacrimal obstruction, active ulcer, glaucoma or ocular herpes
             simplex virus infection

          3. Patients currently using topical steroidal or anti-inflammatory eye drops for 1 month
             prior to screening

          4. Receipt of any type of topical artificial eye drops within 3 days prior to screening

          5. Receipt of topical cyclosporine eye drops within 3 months prior to screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yael Kenan, Ph.D</last_name>
    <phone>972-3-9085028</phone>
    <email>yaelkenan@lacrima-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center, Israel</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elia Levinger, MD</last_name>
      <phone>+972-3-6973408</phone>
      <email>dr.levinger@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elia Levinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 30, 2013</lastchanged_date>
  <firstreceived_date>September 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keratoconjunctivitis Sicca</keyword>
  <keyword>Dry Eye Syndromes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
